Hot Stocks: SCHW rises on earnings, Dell up on analyst comments; Roblox slides on March metrics; Google, MRNA slide
da-kuk

Major market averages saw a flatline in Monday's noon session, as investors remained mostly hesitant due to the first quarter earnings season.
Looking at the individual stocks, Charles Schwab (NYSE:SCHW) gained on better-than-expected Q1 earnings and Dell Technologies (NYSE:DELL) rose on an analyst comment.
Meanwhile, Roblox (NYSE:RBLX) fell after the company released its March metrics report.
Alphabet (NASDAQ:GOOG) shares fell as it was reported that Samsung is considering utilising Microsoft's Bing as the default search engine on its smartphones, which would replace Google, given its recent AI technological breakthroughs.
Moderna (NASDAQ:MRNA) stock fell after the firm released comprehensive Phase 2 results for its mRNA cancer injection in melanoma.
Gainers
The Charles Schwab (SCHW) shares rose by 2.5% as rate hikes by the Federal Reserve boosted the financial services provider's interest income, even as it struggled with a decline in deposits from the U.S. banking crisis last month.
In the meantime, Dell Technologies (DELL) shares rose about 1% despite JPMorgan Analyst Samik Chatterjee lowering his rating on the stock to neutral.
Chatterjee said that there is expected to be a 21% half-year rebound in PC sales, which should enable both HP (HPQ) and Dell (DELL) achieve a "robust ramp in revenue and an even stronger ramp in profits," although the preference is for HP.
Decliners
Roblox (RBLX) shares fell 12% after the company released its March metrics report, which showed anticipated average bookings per daily active users ranging between $3.73 and $3.85. This represents a year-on-year change of -2% to +1%.
Google (GOOG) (NASDAQ:GOOGL) shares dipped more than 3%on the news that Samsung is discussing using Microsoftâs Bing as the default search engine on its devices given its recent AI technology advancements, which would replace Google.
Meanwhile, Moderna (MRNA) fell more than 7% after the company revealed comprehensive mid-stage data for a combination therapy including the vaccine maker's personalised cancer shot mRNA-4157 (V940) and the pharma giant's blockbuster cancer medicine Keytruda at a medical event on Sunday.

To keep track of Wall Street's biggest winners and losers throughout the session, head over to Seeking Alpha's On The Move section.